Datroway (Datopotamab Deruxtecan): MOA, Approvals & India

Reviewed and updated: 4 July 2026. Regulatory approval status, indications, and India commercial-availability status can change. Verify current status against the primary sources in the References section before making clinical, procurement, or regulatory decisions.

In brief: Datopotamab deruxtecan-dlnk is a TROP2-directed antibody-drug conjugate (ADC) marketed as Datroway® in the United States and most global markets, and as Datverzo® in India. As of this writing it holds three FDA approvals — HR-positive/HER2-negative breast cancer (17 Jan 2025) [1], EGFR-mutated non-small cell lung cancer (23 Jun 2025, accelerated approval) [2], and first-line triple-negative breast cancer (22 May 2026) [3] — plus an EU marketing authorisation for the breast-cancer indication [8]. In India, the Central Drugs Standard Control Organisation (CDSCO) approved import, sale, and distribution on 17 December 2025, for the breast-cancer indication, under the brand name Datverzo [4,9]. A commercial launch date and price had not been publicly announced as of this writing.

Also Read:EMRELIS For NSCLC (Telisotuzumab Vedotin): Targeted Hope or Cautious Bet?

Datroway Also Known As

Datopotamab deruxtecan-dlnk is a single molecule sold under two distinct regional brand names, plus a widely used research shorthand:

• Datroway® — brand name in the United States, the European Union, Japan, and most other markets [1,8].
• Datverzo® — the brand name under which the CDSCO approved the same molecule for import, sale, and distribution in India [4,9]. This is a different brand name for the same active substance, not a different drug — a distinction worth flagging explicitly, since “Datroway” and “Datverzo” are sometimes conflated in secondary coverage.
• Dato-DXd — the abbreviation used throughout the clinical and scientific literature, short for “datopotamab deruxtecan” [5,6].
• Datopotamab deruxtecan-dlnk — the full USAN/generic name (the “-dlnk” suffix is the FDA’s biologic naming code); outside the US it is simply datopotamab deruxtecan [1,7,8].

What Is Datopotamab Deruxtecan?

Datopotamab deruxtecan-dlnk is a Trop2-directed antibody and topoisomerase inhibitor conjugate — an antibody-drug conjugate (ADC) — indicated for the treatment of adult patients with specific, biomarker-defined solid tumours [1,7]. It was discovered by Daiichi Sankyo and is jointly developed and commercialised globally with AstraZeneca [4,8]. It is not a self-administered medicine: it is a hazardous, physician-administered oncology biologic given by intravenous infusion in a hospital or infusion-centre setting, under oncologist supervision [7].

Mechanism of Action

Datopotamab deruxtecan-dlnk is built from three linked components, per the FDA-approved product description [7]:

1. A humanized anti-TROP2 IgG1 monoclonal antibody (datopotamab) — TROP2 (trophoblast cell-surface antigen 2) is a transmembrane glycoprotein broadly expressed across several epithelial tumour types, including HR-positive/HER2-negative and triple-negative breast cancer [5,6].
2. A cleavable, tetrapeptide-based linker that remains stable in systemic circulation and is designed to release its payload selectively once inside tumour cells [6,7].
3. DXd, a topoisomerase I inhibitor payload derived from exatecan, attached to the antibody at an average ratio of approximately four DXd molecules per antibody molecule [7].

Mechanistically: after datopotamab binds TROP2 on the surface of a tumour cell, the ADC is internalised, and lysosomal enzymes cleave the linker inside the cell. The released, membrane-permeable DXd then inhibits topoisomerase I, causing DNA damage and apoptotic (programmed) cell death [7]. Because DXd is membrane-permeable, it can also diffuse into neighbouring tumour cells in the microenvironment — including cells that express little or no TROP2 themselves — producing a “bystander” cytotoxic effect that is considered a characteristic feature of this ADC class [6]. This is the same DXd-payload/cleavable-linker chemistry (Daiichi Sankyo’s “DXd ADC technology”) used in trastuzumab deruxtecan (Enhertu); the antibody component is what differs between the two agents (see the comparison section below) [8].

The mechanism has demonstrated anti-tumour activity in nonclinical (mouse) models of breast cancer, in addition to the human efficacy data summarised in the trial sections below [7].

Regulatory Approval Timeline

Datopotamab deruxtecan has accumulated a genuinely multi-jurisdictional, multi-indication approval history since early 2025. The interactive timeline below summarises the key milestones; a text summary follows for reference.

A regulatory-affairs note worth flagging precisely: the EU pathway is often loosely summarised as “approved in January 2025,” but the CHMP’s positive opinion (31 Jan 2025) and the European Commission’s marketing authorisation (8 Apr 2025) are two distinct steps, roughly ten weeks apart [8]. For anyone tracking exact regulatory dates, that distinction matters.

The FDA’s June 2025 NSCLC approval is an accelerated approval, granted on the basis of response-rate and duration-of-response data from a pooled analysis of 114 patients; accelerated approvals of this kind are typically contingent on confirmatory trial data verifying clinical benefit [2].

Datroway Development and Collaborative Innovation

Datopotamab deruxtecan is the product of a global development and commercialisation collaboration between Daiichi Sankyo, which discovered the molecule and owns its proprietary DXd ADC technology, and AstraZeneca, which co-develops and co-commercialises it worldwide [4,8]. The collaboration also covers Enhertu (trastuzumab deruxtecan) and several other DXd-class ADCs in Daiichi Sankyo’s oncology pipeline [8]. Datopotamab deruxtecan is manufactured in Chinese hamster ovary (CHO) cells using recombinant DNA technology; the topoisomerase inhibitor payload and linker are produced by chemical synthesis and conjugated to the antibody at the manufacturing stage [7].

In the United States, the product is jointly marketed by Daiichi Sankyo, Inc. and AstraZeneca Pharmaceuticals LP [7]. In India, the CDSCO approval to import, sell, and distribute the product was granted directly to AstraZeneca Pharma India Limited [4,9].

Availability and Price in India

This is the section most searches land on without a clear answer, so here is the current, verifiable status as of this writing:

• Regulatory status: On 17 December 2025, the CDSCO granted AstraZeneca Pharma India Limited approval to import, sell, and distribute datopotamab deruxtecan in India, as a 100 mg lyophilised powder for concentrate for solution for infusion [4,9].
• Brand name in India: Datverzo — not Datroway. This is a distinct, India-specific brand name for the same molecule, and it’s a genuinely common point of confusion given that most global coverage of the drug uses the Datroway name [9].
• Approved indication in India: the CDSCO approval, as granted, covers adult patients with unresectable or metastatic HR-positive, HER2-negative (IHC 0, IHC 1+, or IHC 2+/ISH-) breast cancer who have received prior endocrine-based therapy and chemotherapy — the same population as the original 2025 US/EU approval. It does not, as of this writing, extend to the EGFR-mutated NSCLC or triple-negative breast cancer indications that were subsequently approved in the US [4,9].
• Commercial launch and price: AstraZeneca Pharma India’s own announcement noted that further information on launch timeline would follow “post all necessary [statutory] approvals” [4]. As of this writing, no commercial launch date or list price has been publicly announced. We have not found a verified Indian price for this product, and we are not going to guess at one — unverified pricing on an oncology biologic is a patient-safety and credibility risk, not a convenience.
• Access before commercial launch: for patients who need the therapy before a commercial launch is confirmed, the standard legal route in India for an approved-but-not-yet-launched biologic is named-patient import, coordinated through a treating oncologist and a licensed importer, under CDSCO’s applicable import framework. This is a general description of the regulatory pathway, not guidance on how to obtain the drug for any individual — that determination sits with the treating oncologist and the hospital’s pharmacy/regulatory team.

Because this status can change quickly, treat the CDSCO notification and the AstraZeneca Pharma India announcement [4,9] as the primary sources to re-check periodically, rather than relying on any single point-in-time summary — including this one.

Side Effects and Safety Warnings

The following is FDA-label information [7], reported here as regulatory/label content — not as treatment guidance. Any decision about whether, when, or how to manage these risks in an individual patient belongs to the treating oncologist, who will weigh renal and hepatic function, body weight, comorbidities, and prior therapy.

Boxed warnings/precautions in the US label:

• Interstitial lung disease (ILD)/pneumonitis — can be severe, life-threatening, or fatal. In TROPION-Breast01, ILD/pneumonitis occurred in 4.2% of patients treated with Datroway (0.5% Grade 3–4; 0.3% fatal), with a median time-to-onset of 3.5 months. The label directs clinicians to withhold treatment for suspected ILD/pneumonitis and permanently discontinue for confirmed Grade 2 or higher disease [7].
• Ocular adverse reactions — occurred in 51% of patients overall, most commonly dry eye (27%) and keratitis (24%), with blepharitis and increased lacrimation (8% each) and meibomian gland dysfunction (7%); 1.9% of patients had Grade 3 ocular events. The label specifies baseline and on-treatment ophthalmic exams, preservative-free lubricating eye drops, and contact-lens avoidance during treatment [7].
• Stomatitis/oral mucositis — occurred in 59% of patients (7% Grade 3–4), with a median time-to-onset of 0.7 months. The label specifies a steroid-containing mouthwash and holding ice chips/ice water during infusion as label-directed supportive measures [7].
• Embryo-fetal toxicity — the DXd payload is genotoxic and affects actively dividing cells; the label states Datroway can cause fetal harm and directs effective contraception during treatment and for 7 months after the last dose (patients who can become pregnant) or 4 months after the last dose (male patients with partners who can become pregnant) [7].

Other common adverse reactions (≥20% in TROPION-Breast01, all grades): nausea, fatigue, decreased leukocytes, decreased calcium, alopecia, decreased lymphocytes, decreased haemoglobin, constipation, decreased neutrophils, vomiting, increased ALT/AST, and increased alkaline phosphatase [7].

Dosing, per label (not a recommendation): the FDA label specifies 6 mg/kg by IV infusion once every three weeks (21-day cycle), up to a maximum of 540 mg for patients ≥90 kg, with defined dose-reduction steps for specific adverse reactions and no re-escalation after a reduction [7]. This is presented here as the labelled regimen, not as guidance for any individual patient — actual dosing, premedication, and monitoring are determined by the treating oncologist based on renal/hepatic function, body weight, comorbidities, and prior therapy.

Datroway vs. Enhertu

Both agents are DXd-class antibody-drug conjugates from the same Daiichi Sankyo/AstraZeneca collaboration, and both are frequently searched together — but they target different biomarkers and, as a result, have different (and differently mature) indication sets.

This is a factual comparison of target, mechanism, and regulatory status only — it is not a recommendation of one agent over the other. Selecting between TROP2- and HER2-directed therapy (or neither) for a specific patient depends on biomarker testing, prior treatment, and clinical judgement, and is a decision for the treating oncologist.

Datopotamab Deruxtecan Animal Testing Data

Two distinct categories of nonclinical (animal) data appear in the FDA label, and they are worth keeping separate [7]:

• Reproductive/developmental toxicity: the label states plainly that no dedicated animal reproductive or developmental toxicity studies were conducted with datopotamab deruxtecan-dlnk. The embryo-fetal risk warning is therefore based on the drug’s mechanism of action (DXd is genotoxic and affects actively dividing cells) rather than on animal reproductive-toxicology data specific to this molecule [7]. For general context, the label notes that in the US general population, the background risk of major birth defects in clinically recognised pregnancies is estimated at 2–4%, and of miscarriage at 15–20% — baseline population figures, not drug-attributable risk estimates [7].
• General (non-reproductive) toxicology: a 3-month repeat-dose toxicity study in rats, at doses roughly 29 times the human AUC exposure at the recommended dose, found decreased testicular/epididymal weight, germinal epithelium degeneration, and reduced sperm counts in males, and increased atretic ovarian follicles and vaginal mucosal changes in females. Most of these findings — with the exception of some testicular/epididymal changes — were not observed after a 2-month recovery period [7]. Separately, DXd was clastogenic in an in vivo rat bone-marrow micronucleus assay and an in vitro chromosome-aberration assay, though not mutagenic in a bacterial reverse-mutation assay [7]. Mouse-model data cited in the label’s mechanism-of-action section also demonstrated anti-tumour activity for the ADC in a breast-cancer model [7].

If you are pregnant, may become pregnant, or are planning a pregnancy, this is a conversation for your treating oncologist — not a determination to make from label text alone.

TROPION-Breast01 Trial

TROPION-Breast01 (NCT05104866) is the pivotal, global, multicentre, open-label, randomised phase 3 trial that supported the original January 2025 FDA and EU approvals [1,5,7,8].

Design: 732 adult patients with unresectable or metastatic HR-positive, HER2-negative breast cancer (IHC 0, IHC 1+, or IHC 2+/ISH-) who had progressed on/were unsuitable for further endocrine therapy, and had received one or two prior lines of chemotherapy, were randomised 1:1 to datopotamab deruxtecan 6 mg/kg IV every three weeks (n=365) or investigator’s choice of single-agent chemotherapy — eribulin, capecitabine, vinorelbine, or gemcitabine (n=367) [5,7]. Dual primary endpoints were progression-free survival (PFS) by blinded independent central review and overall survival (OS) [7].

Results (Table 7 of the FDA label) [7]:

A detail worth stating plainly, given how often it gets glossed over: the PFS benefit was statistically significant and formed the primary basis for approval, but the OS result did not reach statistical significance at the data cut-off reported in the label [7]. This is a recognised point of clinical discussion in the ADC literature — some commentators have noted it represents an approval based on a positive PFS result without a corresponding OS benefit at the time of approval, in a disease setting where subsequent-therapy crossover can complicate OS interpretation [5,7].

Other Pivotal Trials at a Glance

• TROPION-Lung05 and TROPION-Lung01 — supported the June 2025 accelerated approval in EGFR-mutated NSCLC, via a pooled analysis of 114 patients with locally advanced/metastatic disease who had progressed on prior EGFR-directed therapy and platinum-based chemotherapy; confirmed ORR was 45%, with a median duration of response of 6.5 months [2].
• TROPION-Breast02 (NCT05374512) — supported the May 2026 first-line TNBC approval; 644 patients not eligible for PD-1/PD-L1 inhibitor therapy were randomised to datopotamab deruxtecan or investigator’s choice of chemotherapy, showing median PFS of 10.8 vs. 5.6 months (HR 0.57) and median OS of 23.7 vs. 18.7 months (HR 0.79) — notably, this trial did show a statistically significant OS benefit [3,6].

Frequently Asked Questions

What is Datroway used for?

Datroway (datopotamab deruxtecan-dlnk) is an FDA-approved antibody-drug conjugate. As of this writing it is approved for adults with unresectable or metastatic HR-positive, HER2-negative breast cancer after prior endocrine therapy and chemotherapy [1]; EGFR-mutated non-small cell lung cancer after prior EGFR-directed therapy and platinum-based chemotherapy [2]; and first-line, PD-1/PD-L1-ineligible triple-negative breast cancer [3].

Is Datroway available in India?

The molecule is CDSCO-approved for import, sale, and distribution in India as of 17 December 2025, but under the brand name Datverzo, not Datroway, and only for the breast-cancer indication [4,9]. A commercial launch date and price have not been publicly announced as of this writing; named-patient import is the standard legal route before a commercial launch, coordinated through a treating oncologist.

How does Datopotamab Deruxtecan work?

It is a TROP2-directed antibody attached to a topoisomerase I inhibitor payload (DXd) via a cleavable linker. After binding TROP2 on tumour cells, the ADC is internalised, the linker is cleaved intracellularly, and the released DXd causes DNA damage and cell death — with some spillover (“bystander”) effect on neighbouring tumour cells [6,7].

What are the side effects of Datroway?

Per the FDA label, the most significant risks are interstitial lung disease/pneumonitis, ocular adverse reactions (including keratitis), stomatitis/oral mucositis, and embryo-fetal toxicity, alongside common adverse reactions including nausea, fatigue, and cytopenias [7]. This is label information, not a substitute for guidance from a treating oncologist, who monitors and manages these risks individually.

References

1. U.S. Food and Drug Administration. FDA approves datopotamab deruxtecan-dlnk for unresectable or metastatic, HR-positive, HER2-negative breast cancer [Internet]. Silver Spring (MD): FDA; 2025 Jan 17 [cited 2026 Jul 4]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-datopotamab-deruxtecan-dlnk-unresectable-or-metastatic-hr-positive-her2-negative-breast
2. U.S. Food and Drug Administration. FDA grants accelerated approval to datopotamab deruxtecan-dlnk for EGFR-mutated non-small cell lung cancer [Internet]. Silver Spring (MD): FDA; 2025 Jun 23 [cited 2026 Jul 4]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-datopotamab-deruxtecan-dlnk-egfr-mutated-non-small-cell-lung-cancer
3. U.S. Food and Drug Administration. FDA approves datopotamab deruxtecan-dlnk for unresectable or metastatic triple-negative breast cancer [Internet]. Silver Spring (MD): FDA; 2026 May 22 [cited 2026 Jul 4]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-datopotamab-deruxtecan-dlnk-unresectable-or-metastatic-triple-negative-breast-cancer
4. AstraZeneca Pharma India Ltd. AstraZeneca Pharma India receives CDSCO approval for Datopotamab Deruxtecan, a TROP2-directed antibody drug conjugate, for the treatment of metastatic breast cancer [Internet]. Bangalore: AstraZeneca; 2025 Dec 17 [cited 2026 Jul 4]. Available from: https://www.astrazeneca.in/media/press-releases/2025/astrazeneca-pharma-india-receives-cdsco-approval-for-datopotamab-deruxtecan.html
5. Bardia A, Jhaveri K, Kalinsky K, et al. TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2– breast cancer. Future Oncol. 2024;20(8):423–436.
6. Dent R, Shao Z, Schmid P, et al. Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial. Ann Oncol. 2026; doi:10.1016/j.annonc.2026.03.008.
7. U.S. Food and Drug Administration. Highlights of prescribing information: DATROWAY (datopotamab deruxtecan-dlnk) [Internet]. Silver Spring (MD): FDA; 2025 [cited 2026 Jul 4]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761394s000lbl.pdf
8. European Medicines Agency. Datopotamab deruxtecan Daiichi Sankyo (Datroway): European public assessment report [Internet]. Amsterdam: EMA; 2025 [cited 2026 Jul 4]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/datopotamab-deruxtecan-daiichi-sankyo
9. Sharma R. AstraZeneca Pharma India wins CDSCO permission to import breast cancer drug Datverzo [Internet]. Medical Dialogues; 2025 Dec 18 [cited 2026 Jul 4]. Available from: https://medicaldialogues.in/news/industry/pharma/astrazeneca-pharma-india-wins-cdsco-permission-to-import-breast-cancer-drug-datverzo-160885

This article is written for oncologists, hospital pharmacists, regulatory affairs professionals, and distributors, and is intended as regulatory/scientific reference information — not as treatment guidance for patients. It does not recommend any dosing, treatment, or purchasing decision. Consult the primary regulatory sources linked above, and a treating oncologist, for any patient-specific decision.